In this research, after treatment of lung cancer cells with BRC, high expression levels of DRD2 were found and at a low dosage of the drug in conjugated form, this effect was found to be stronger while having more potent anti-cancer effects and less toxicity. This evidence concerns the gene DRD2 and lung carcinoma.